Therapy News and Research

RSS

Publicly released report cards do not appear to improve hospitals' performance, says new study

An analysis of quality of cardiac care following the public release of data on measures of care at hospitals in Ontario, Canada, did not result in significant systemwide improvement in hospitals' performance on most quality of care indicators, according to a study to be published in the December 2 issue of JAMA. The study is being released early online because of its presentation at an American Heart Association scientific conference.

19 Nov 2009

iCAD and AdMeTech Foundation sign a strategic partnership agreement

iCAD, Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announces a strategic partnership with the AdMeTech Foundation, a non-profit organization with a mission to end prostate cancer as a patient care crisis and socio-economic problem.

19 Nov 2009

Radiation breakthrough to treat breast cancer patients in one day arrives at CTCA

A radiation breakthrough to treat breast cancer patients in one day, as opposed to the current average of six weeks, has arrived at Cancer Treatment Centers of America(R) (CTCA) in Philadelphia. CTCA will become the first in the country to offer this treatment option using the Novac7 technology from Rome, Italy.

19 Nov 2009

New research on viral activity may aid in treating bacterial infections

Viruses are well known for attacking humans and animals, but some viruses instead attack bacteria. Texas A&M University researchers are exploring how hungry viruses, armed with transformer-like weapons, attack bacteria, which may aid in the treatment of bacterial infections.

19 Nov 2009

Dual niacin-statin therapy improves blood cholesterol levels but does not diminish plaque buildup

The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows.

19 Nov 2009

Once-a-day dosing clinical study of udenafil for erectile dysfunction completed

Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced today that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED).

19 Nov 2009

Nicardipine Hydrochloride Injection for short-term treatment of hypertension launched

Caraco Pharmaceutical Laboratories, Ltd. has launched Nicardipine Hydrochloride Injection immediately following Sun Pharma's final approval from the US Food and Drug Administration (FDA).

19 Nov 2009

Update on FDA's review of BSD-2000 Hyperthermia System for patients with cervical carcinoma provided

BSD Medical Corporation (www.bsdmedical.com) today provided an update on the U.S. Food and Drug Administration’s (FDA) review of the Company's Humanitarian Device Exemption (HDE) marketing submission for the Company’s BSD-2000 Hyperthermia System.

18 Nov 2009

GTS, the first company to develop and commercialize a unique form of ultrasound technology

Guided Therapy Systems, LLC (GTS), a leading medical technology company, is the first company in the world to develop and commercialize products that employ a unique form of ultrasound technology, Intense Therapeutic Ultrasound (ITU).

18 Nov 2009

Also in Global Health news: Sleeping sickness; aid for Philippines; U.S., China in Africa; polio eradication in Afghanistan; Ethiopia famine

Lancet Infectious Diseases Newsdesk examines how despite evidence that a new therapy to treat sleeping sickness, called nifurtimox—eflornithine (NECT) is a step forward in treating the disease, it has yet to be implemented by countries "13 months after data from a successful trial was presented." The main issue at hand - "nifurtimox is not registered for use in sleeping sickness," the journal writes. The article also examines other factors complicating the implementation of the therapy (Morris, 12/09).

18 Nov 2009

CEL-SCI commences clinical study of LEAPS-H1N1 treatment for hospitalized patients

CEL-SCI Corporation, a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today the start of the Company's first clinical study for hospitalized H1N1 patients at The Johns Hopkins University School of Medicine (Johns Hopkins).

18 Nov 2009

St. Jude Medical announces implantation of the first patient in China with its Eon rechargeable neurostimulator

St. Jude Medical, Inc. announced today that a 62-year-old man from Shenzhen, Guangdong province has become the first patient in China to be implanted with the Eon™ neurostimulator, a rechargeable device used to help manage chronic pain. Despite prior back surgeries, the patient suffered from chronic back pain for more than a decade.

18 Nov 2009

Key findings from AstraZeneca's phase II studies of ticagrelor

AstraZeneca today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (BRILINTA(TM)) at the annual American Heart Association (AHA) Scientific Sessions in Orlando, FL,with ONSET/OFFSET study results being simultaneously published in the medical journal Circulation.

18 Nov 2009

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.

18 Nov 2009

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

CytRx Corporation, a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer.

18 Nov 2009

Way to capture tumor cells in the bloodstream discovered

A team led by University of Arkansas for Medical Sciences (UAMS) researchers on the cutting edge of nanotechnology has found a way to capture tumor cells in the bloodstream that could dramatically improve earlier cancer diagnosis and prevent deadly metastasis.

18 Nov 2009

Pfizer Canada accepts Prix Galien Canada 2009 Innovative Product Award for CHAMPIX

Pfizer Canada accepted the Prix Galien Canada 2009 Innovative Product Award for CHAMPIX (varenicline tartrate), the first prescription treatment for smoking cessation in adults specifically designed to target nicotine addiction. The award was presented last night at a gala in Ottawa recognizing excellence in pharmaceutical research.

18 Nov 2009

Positive results from REVIVE, a phase 3 pivotal study of avanafil announced

VIVUS, Inc. today announced positive results from REVIVE (TA-301), a phase 3 pivotal study evaluating the safety and efficacy of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED), in 646 patients.

18 Nov 2009

MU occupational therapy professor says recovery from brain injuries can last a lifetime

Until recently, scientists believed that, following a stroke, a patient had about six months to regain any lost function. After that, patients would be forced to compensate for the lost function by focusing on their remaining abilities. Although this belief has been refuted, a University of Missouri occupational therapy professor believes that the current health system is still not giving patients enough time to recover and underestimating what the human brain can do given the right conditions.

18 Nov 2009

New study explores consumers' choice in health remedies

Alternative health remedies are increasingly important in the health care marketplace. A new study in the Journal of Consumer Research explores how consumers choose among the many available remedies.

18 Nov 2009

Therapy News and Research

Publicly released report cards do not appear to improve hospitals' performance, says new study

iCAD and AdMeTech Foundation sign a strategic partnership agreement

Radiation breakthrough to treat breast cancer patients in one day arrives at CTCA

New research on viral activity may aid in treating bacterial infections

Dual niacin-statin therapy improves blood cholesterol levels but does not diminish plaque buildup

Once-a-day dosing clinical study of udenafil for erectile dysfunction completed

Nicardipine Hydrochloride Injection for short-term treatment of hypertension launched

Update on FDA's review of BSD-2000 Hyperthermia System for patients with cervical carcinoma provided

GTS, the first company to develop and commercialize a unique form of ultrasound technology

Also in Global Health news: Sleeping sickness; aid for Philippines; U.S., China in Africa; polio eradication in Afghanistan; Ethiopia famine

CEL-SCI commences clinical study of LEAPS-H1N1 treatment for hospitalized patients

St. Jude Medical announces implantation of the first patient in China with its Eon rechargeable neurostimulator

Key findings from AstraZeneca's phase II studies of ticagrelor

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

Way to capture tumor cells in the bloodstream discovered

Pfizer Canada accepts Prix Galien Canada 2009 Innovative Product Award for CHAMPIX

Positive results from REVIVE, a phase 3 pivotal study of avanafil announced

MU occupational therapy professor says recovery from brain injuries can last a lifetime

New study explores consumers' choice in health remedies

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News